Discovery of novel enasidenib analogues targeting inhibition of mutant isocitrate dehydrogenase 2 as antileukaemic agents

Mutant isocitrate dehydrogenase (IDH) 2 “IDH2m” acquires a neo-enzymatic activity reducing α-ketoglutarate to an oncometabolite, D-2-hydroxyglutarate (2-HG). Three s-triazine series were designed and synthesised using enasidenib as a lead compound. In vitro anticancer screening via National Cancer I...

Descripción completa

Detalles Bibliográficos
Autores principales: Khalil, Ahmed F., El-Moselhy, Tarek F., El-Bastawissy, Eman A., Abdelhady, Rasha, Younis, Nancy S., El-Hamamsy, Mervat H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9848300/
https://www.ncbi.nlm.nih.gov/pubmed/36629449
http://dx.doi.org/10.1080/14756366.2022.2157411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9848300/
https://www.ncbi.nlm.nih.gov/pubmed/36629449
http://dx.doi.org/10.1080/14756366.2022.2157411

Ejemplares similares